CAR-A therapy (chimeric antigen receptor astrocyte therapy) represents a novel adoptive immunotherapy approach for Alzheimer's disease (AD) that engineers astrocytes to express anti-amyloid-β chimeric antigen receptors. This emerging strategy aims to target and clear amyloid-β plaques directly in the brain, addressing the underlying pathology of AD rather than just managing symptoms.
Alzheimer's disease is the leading cause of dementia, characterized by progressive amyloid accumulation followed by tau-mediated neurodegeneration. Despite significant advances in anti-amyloid immunotherapies such as lecanemab (Leqembi) and donanemab, important limitations remain — including limited efficacy, high cost, and significant side effects such as amyloid-related imaging abnormalities (ARIA)[1][2].
CAR-A therapy offers a fundamentally different approach by harnessing astrocytes — the most abundant glial cells in the brain — as therapeutic vehicles that can be genetically engineered to recognize and eliminate amyloid-β deposits directly within the central nervous system[3].
CAR-A therapy involves the engineering of astrocytes to express chimeric antigen receptors (CARs) specifically designed to bind amyloid-β. The mechanism includes several key components:
The CAR constructs consist of an extracellular amyloid-β targeting domain (typically an anti-Aβ scFv antibody), a transmembrane domain, and intracellular signaling domains that activate astrocyte responses upon ligand binding[3:1].
Once engineered, CAR-A cells can:
Research has demonstrated that different CAR-A constructs produce distinct, receptor-specific effects in astrocytes and microglia, allowing for optimization of therapeutic outcomes[3:3].
A landmark study published in Science (2026) by Chen et al. demonstrated proof-of-concept for CAR-A therapy in preclinical models[3:4]:
CAR-A therapy differs from existing anti-amyloid immunotherapies in several important ways:
| Feature | CAR-A Therapy | Passive Antibodies (Lecanemab/Donanemab) | Active Immunotherapy |
|---|---|---|---|
| Delivery | Gene therapy (AAV vector) | Intravenous infusion | Vaccine |
| Targeting | Local (brain-resident astrocytes) | Peripheral→central | Peripheral→central |
| Duration | Long-term expression | Requires repeated dosing | Sustained response |
| Side Effect Profile | Unknown (under investigation) | ARIA risk | Potential for brain edema |
| Manufacturing | Complex (gene therapy) | Biologic manufacturing | Vaccine platform |
While CAR-A therapy represents a promising disease-modifying strategy, significant development is required before clinical translation. The Science paper establishes foundational proof-of-concept that supports further investigation[3:7].
ALZFORUM Therapeutics Database. Amyloid-Related immunotherapies. Retrieved 2026-03-21 from. https://www.alzforum.org/therapeutics. 2026. ↩︎
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. The New England Journal of Medicine. 2023;388(1):9-21. 36424313. 2023. ↩︎
Chen Y, Liu Y, Nguyen K, et al. Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy. Science. 2026. 10.1126/science.ads3972. 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎